OncoMatch/Clinical Trials/NCT06084936
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Is NCT06084936 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for lymphoma.
Treatment: Obinutuzumab · Glofitamab · Rituximab · Bendamustine · Lenalidomide · Tocilizumab — The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CCND1 overexpression
Required: CCND1 t(11:14)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: BTK inhibitor
At least 1 line of prior systemic therapy including a BTK inhibitor and additional systemic therapy option
Cannot have received: bispecific antibody targeting both CD20 and CD3 (glofitamab)
Prior treatment with glofitamab or other bispecific antibodies targeting both CD20 and CD3
Cannot have received: CAR-T cell therapy
Prior treatment with CAR-T cell therapy
Cannot have received: systemic therapy or BTK inhibitors or any investigational agent for the purposes of treating cancer
Exception: within 2 weeks or 5 half-lives (whichever is shorter) prior to first study treatment
Treatment with systemic therapy or BTK inhibitors, or any investigational agent for the purposes of treating cancer within 2 weeks or 5 half-lives (whichever is shorter) prior to first study treatment
Cannot have received: systemic immunosuppressive medications
Exception: within 2 weeks or five half-lives (whichever is shorter) prior to the first dose of study treatment
Prior treatment with systemic immunosuppressive medications within 2 weeks or five half-lives (whichever is shorter) prior to the first dose of study treatment
Cannot have received: corticosteroid therapy
Exception: within 2 weeks prior to first dose of study treatment
Corticosteroid therapy within 2 weeks prior to first dose of study treatment
Cannot have received: live, attenuated vaccine
Exception: within 4 weeks before first study treatment administration or anticipation that such a live, attenuated vaccine will be required during the study
Administration of a live, attenuated vaccine within 4 weeks before first study treatment administration or anticipation that such a live, attenuated vaccine will be required during the study
Cannot have received: solid organ transplantation or allogenic stem cell transplant
Prior solid organ transplantation or allogenic stem cell transplant
Lab requirements
Blood counts
adequate hematological function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Alta Bates Summit Medical Center · Berkeley, California
- City of Hope Cancer Center · Duarte, California
- University of California Los Angeles (UCLA) - Cancer Care - Santa Monica · Santa Monica, California
- Yale Cancer Center · New Haven, Connecticut
- Georgetown University · Washington D.C., District of Columbia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify